Search the MBS

Standard Search

Advanced Search Search Tips

Enter keywords or item numbers below
Search Options

Results 1 to 2 of 2 matches

Category 6 - PATHOLOGY SERVICES

PN.1.2

Exemptions to Basic Requirements

Related Items: 69303 69306 69312 69318 69321 69345 69494 69495 69496 71147 72813 72838 72846 72847 72848 72849 72850 72851 72852 72860 73045 73051 73059 73060 73061 73300 73305 73320 73332 73336 73337 73342 73344 73364 73383 73389 73410 73411 73412 73413 73429 73436 73437 73438 73439

Category 6 - PATHOLOGY SERVICES

73336

73336 - Additional Information

Item Start Date:
01-Dec-2013
Description Updated:
01-Apr-2020
Schedule Fee Updated:
01-Dec-2013

Group
P7 - Genetics

A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.



Fee: $230.95 Benefit: 75% = $173.25 85% = $196.35

(See para PN.1.2 of explanatory notes to this Category)

Results 1 to 2 of 2 matches

Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change